A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Two fit and healthy young men who were diagnosed with stage three colon cancer in their 30s have revealed the symptoms not to miss. Chris Lopez, from Texas, was lean, regularly worked out at the ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

Exploring the link between liver cirrhosis and liver metastasis in colorectal cancer. Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and ...

James Van Der Beek thanked his father for guiding him physically and emotionally through his colorectal cancer diagnosis in a ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a molecular residual disease test could be instrumental in improving treatment ...